Table 1—

Changes in glycemic control during the study and glycemic variables after 4 weeks treatment

Two doses repaglinide
Three doses repaglinide
P between groups
Baseline4 weeksChange from baselineP for change from baselineBaseline4 weeksChange from baselineP for change from baseline
Glycemic control
    Fasting glucose (mmol/l)11.3 (2.3)9.6 (2.1)−1.7 (1.2)*0.002111.1 (3.3)8.4 (2.0)−2.7 (2.6)0.03110.3724
    2-h postprandial glucose (mmol/l)
        Breakfast15.0 (2.8)10.7 (2.8)−4.3 (2.4)*0.000613.7 (4.9)8.2 (3.0)−5.5 (3.3)*0.00470.4063
        Lunch10.7 (2.8)9.0 (2.1)−1.7 (2.2)0.04509.8 (3.7)6.2 (1.6)−3.7 (2.9)0.01510.1449
        Evening meal13.3 (2.1)12.1 (2.2)−1.2 (1.6)0.051413.6 (3.9)9.8 (1.8)−3.8 (2.5)*0.00730.0247
    HbA1c (%)7.1 (0.7)6.8 (1.0)−0.3 (0.6)0.1797.5 (2.0)6.5 (1.7)−1.0 (0.7)*0.0040.028
Glycemic variables
    Glucose AUC (normed, mmol/l)
        0–24 h8.91 (1.74)7.00 (1.50)0.036
        0–16 h9.38 (1.79)7.37 (1.75)0.041
    Glucose Cmax (mmol/l)
        0–4 h14.41 (2.46)13.02 (2.36)0.273
        4–10 h10.07 (2.17)8.11 (1.33)0.055
        10–16 h12.70 (1.88)10.48 (2.11)0.043
    Glucose Cmin (mmol/l)
        0–4 h7.28 (2.66)5.04 (1.92)0.081
        4–10 h6.91 (1.39)5.30 (1.21)0.030
        10–16 h7.69 (2.28)6.06 (1.52)0.124
  • Data are means (SD).

  • *

    * P < 0.01 for change from baseline;

  • P < 0.05 for change from baseline;

  • P < 0.05 for change between groups.

  • Cmax, maximum concentration reached;

  • Cmin, minimum concentration reached (nadir).